EVT:XETRA Evotec SE

EUR 8.87 0.19 2.130109
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

EUR 8.87

+0.19 (+2.13)%

EUR 1.57B

0.71M

N/A

EUR 35.00 (+294.59%)

Icon

EVT:XETRA

Evotec SE (EUR)
COMMON STOCK | XETRA
EUR 8.87
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

EUR 1.57B

EUR 35.00 (+294.59%)

EUR 8.87

Evotec SE (EVT:XETRA) Stock Forecast

N/A

Based on the Evotec SE stock forecast from 0 analysts, the average analyst target price for Evotec SE is not available over the next 12 months. Evotec SE’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Evotec SE is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Evotec SE’s stock price was EUR 8.87. Evotec SE’s stock price has changed by -0.62% over the past week, -6.83% over the past month and -60.68% over the last year.

No recent analyst target price found for Evotec SE
No recent average analyst rating found for Evotec SE

Company Overview Evotec SE

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunol...Read More

https://www.evotec.com

Essener Bogen 7, Hamburg, Germany, 22419

5,055

December

EUR

Germany

Adjusted Closing Price for Evotec SE (EVT:XETRA)

Loading...

Unadjusted Closing Price for Evotec SE (EVT:XETRA)

Loading...

Share Trading Volume for Evotec SE Shares

Loading...

Compare Performance of Evotec SE Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for EVT:XETRA

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Evotec SE (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRK:XETRA
Merck & Company Inc -0.10 (-0.06%) EUR74.69B 27.44 13.13

ETFs Containing EVT

Symbol Name EVT's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Evotec SE (EVT:XETRA) Stock

Stock Target Advisor's fundamental analysis for Evotec SE's stock is Bearish.

Unfortunately we do not have enough data on EVT:XETRA's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on EVT:XETRA's stock to indicate what its average analyst target is.

EVT:XETRA stock's Price/Earning ratio is 460.50. Our analysis grades EVT:XETRA stock's Price / Earning ratio at F. This means that EVT:XETRA stock's Price/Earning ratio is above 87% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the XETRA exchange. Based on this EVT:XETRA may be a overvalued for its sector.

The last closing price of EVT:XETRA's stock was EUR 8.87.

The most recent market capitalization for EVT:XETRA is EUR 1.57B.

Unfortunately we do not have enough analyst data on EVT:XETRA's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Evotec SE's stock.

As per our most recent records Evotec SE has 5,055 Employees.

Evotec SE's registered address is Essener Bogen 7, Hamburg, Germany, 22419. You can get more information about it from Evotec SE's website at https://www.evotec.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...